Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 29.5% in November

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 4,970,000 shares, a drop of 29.5% from the October 31st total of 7,050,000 shares. Based on an average daily volume of 2,060,000 shares, the days-to-cover ratio is currently 2.4 days.

Zentalis Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ ZNTL opened at $3.61 on Friday. The business has a 50-day moving average price of $3.38 and a 200 day moving average price of $4.93. The stock has a market cap of $257.25 million, a PE ratio of -1.48 and a beta of 1.74. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Analyst Ratings Changes

ZNTL has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Barclays PLC increased its position in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after acquiring an additional 11,748 shares during the period. XTX Topco Ltd grew its stake in shares of Zentalis Pharmaceuticals by 8.7% in the 3rd quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after purchasing an additional 15,597 shares during the last quarter. Quarry LP acquired a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $55,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.